一种用于克服非小细胞肺癌治疗中抗原异质性的多靶向 CAR-T 细胞平台
A Multi-Targeting Chimeric Antigen Receptor-T Cell Platform to Overcome Antigen Heterogeneity in the Treatment of Non-Small Cell Lung Cancer.
这些发现支持采用多靶点CAR-T 策略来应对NSCLC及可能其他实体瘤中的抗原异质性。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Deletion of PD-1 destabilizes the lineage identity and metabolic fitness of tumor-infiltrating regulatory T cells.
Deletion of PD-1 destabilizes the lineage identity and metabolic fitness of tumor-infiltrating regulatory T cells.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
调节性T(T reg)细胞具有免疫抑制功能,并在肿瘤微环境中高表达免疫检查点受体PD-1;然而,PD-1在肿瘤浸润(TI)T reg细胞中的功能仍存在争议。在此,我们发现T reg细胞中PD-1的条件性缺失可延缓肿瘤进展。在Pdcd1 fl/fl Foxp3 eGFP-Cre-ERT2(+/-)小鼠中,表达PD-1的T reg细胞和PD-1缺陷的T reg细胞共存于同一组织环境中,T reg细胞中PD-1的条件性缺失导致TI T reg细胞的增殖和抑制能力受损。PD-1抗体治疗减少了TI T reg细胞数量,但并未直接恢复TC-1肺癌中TI CD8 + T细胞的细胞因子产生。单细胞分析表明,PD-1信号促进TI T reg细胞中的脂质代谢、增殖和抑制通路。这些结果表明,PD-1消融或抑制可通过削弱肿瘤微环境中T reg细胞谱系稳定性和代谢适应性来增强抗肿瘤免疫。
Regulatory T (T reg ) cells have an immunosuppressive function and highly express the immune checkpoint receptor PD-1 in the tumor microenvironment; however, the function of PD-1 in tumor-infiltrating (TI) T reg cells remains controversial.
Here, we showed that conditional deletion of PD-1 in T reg cells delayed tumor progression. In Pdcd1 fl/fl Foxp3 eGFP-Cre-ERT2(+/-) mice, in which both PD-1-expressing and PD-1-deficient T reg cells coexisted in the same tissue environment, conditional deletion of PD-1 in T reg cells resulted in impairment of the proliferative and suppressive capacity of TI T reg cells.
PD-1 antibody therapy reduced the TI T reg cell numbers, but did not directly restore the cytokine production of TI CD8 + T cells in TC-1 lung cancer. Single-cell analysis indicated that PD-1 signaling promoted lipid metabolism, proliferation and suppressive pathways in TI T reg cells. These results suggest that PD-1 ablation or inhibition can enhance antitumor immunity by weakening T reg cell lineage stability and metabolic fitness in the tumor microenvironment.
MEMBER ACCOUNT
登录成功会直接打开下一页。